Introduction
============

The serotonin system is involved in a wide range of fundamental physiological functions like regulation of mood, sleep and appetite ([@ref-12]). Furthermore, serotonergic neurotransmission is implicated in higher brain functions such as cognitive performance ([@ref-22]) and in several psychiatric disorders, including depression, autism, anxiety disorders and schizophrenia ([@ref-12]; [@ref-11]).

With regard to personality, the serotonin system has been linked to the trait self-transcendence (ST) in both Positron Emission Tomography (PET) and genetic studies ([@ref-3]; [@ref-16]; [@ref-28]; [@ref-32]; [@ref-1]; [@ref-39]; [@ref-26]). ST refers to the degree to which an individual feels part of nature and the universe at large, and to extraordinary experiences such as extra sensory perception and sense of a transcendent being or presence ([@ref-15]). The association has been interpreted as evidence for a role for the serotonin system in spiritual experiences, as well as providing a putative mechanism for the involvement of serotonin in psychosis, since high scores in ST has been linked to the schizophrenia spectrum disorders ([@ref-33]).

Our group previously reported a negative correlation between 5-HT~1A~ receptor binding potential (BP~ND~), as measured with PET and the radioligand \[^11^C\]WAY-100635, and ST as measured using Temperament and Character Inventory (TCI). The association was strongest for the subscale spiritual acceptance (SA) ([@ref-3]). However, the results could not be replicated in a subsequent PET study at an independent centre ([@ref-25]). These studies contained 15 and 20 healthy participants, respectively, and therefore, a replication study in a larger sample is required.

Aims of the study
-----------------

The aim of the present study was to perform a replication of our original finding of a negative correlation between 5-HT~1A~ receptor BP~ND~ and ST/SA in a larger sample. In addition to traditional frequentist statistics, we made use of Bayesian hypothesis testing, which allows us not only to test a hypothesis, but also to quantify the relative probability of the observed data under competing hypotheses. Recently replication Bayes factors (BF) have been introduced ([@ref-43]; [@ref-46]), allowing researchers to evaluate replication success by taking the outcome of the previous study fully into account. In this way, we aimed to evaluate the relationship between 5-HT~1A~ receptor binding and ST/SA from the perspective both of hypothesis testing without consideration of the magnitude of previous results, and of replication success.

Material and Methods
====================

Subjects
--------

The sample consisted of 50 healthy men: 12 were enrolled as control subjects in a series of different pharmacological studies (for details see [@ref-30]; 38 in a twin study ([@ref-4]). Age ranged from 21 to 55 (Mean = 30, SD = 5 years). The studies were approved by the Regional Ethics Committee in Stockholm and the Radiation Safety Committee of the Karolinska Hospital, and all subjects provided written informed consent prior to their participation in the studies (IRB 2008/60-31/3; for serotonin markers 2013/136-32).

MR and PET data acquisition (5-HT~1A~ binding potential)
--------------------------------------------------------

Magnetic Resonance Imaging (MRI) images were acquired using a 1.5TGE Signa system (Milwaukee, WI, USA). T1- and T2-weighted MRI images were acquired for all subjects. The PET system used was Siemens ECAT Exact HR 47 (CTI/Siemens, Knoxville, TN, USA). All subjects were examined using \[^11^C\]WAY-100635; The injected radioactivity was 276 ± 35 MBq (mean; SD). BP~ND~ values were calculated for the same regions as examined in the original study ([@ref-3]): frontal cortex, hippocampus (using the simplified reference tissue model - SRTM) and dorsal raphe nucleus (using a wavelet-based method using the non-invasive Logan plot in order to reduce the noise in this small region). For detailed description see [@ref-30]. Other regions were not included in the analysis as they were not part of the original study. However, since \[^11^C\]WAY100635 BP~ND~ is highly correlated between regions, the inclusion of more regions would therefore be unlikely to provide unique information from the three included regions ([@ref-5]).

Personality assessment
----------------------

The Swedish translation of the TCI self-report questionnaire was used ([@ref-7]). It consists of 238 true/false items covering four temperament dimensions (novelty seeking, harm avoidance, reward dependence, and persistence) and three character dimensions (self-directedness, cooperativeness, and self-transcendence). Individual scores were calculated for ST and its subscale SA.

Statistical analysis
--------------------

Pearson's correlation coefficients and their corresponding *p*-values were calculated for the correlation between ST/SA and 5-HT~1A~ BP~ND~ in the frontal cortex, hippocampus and dorsal raphe nucleus. Two BF tests were performed for each comparison. Firstly, we calculated a default correlation BF for the association between BP~ND~ and the ST/SA scores in frontal cortex, hippocampus and dorsal raphe nucleus respectively. Since we specifically wanted to test a negative correlation, we choose a one-sided default Bayes factor test, with a negative Beta prior of width 1 (i.e., flat between −1 and 0) using JASP ([@ref-20]). This test compares the predictive adequacy of the null hypothesis *H*~0~ (i.e., no correlation) with an alternative hypothesis *H*~-~ (i.e., a negative correlation) (for more details on Bayes factors, see ([@ref-29]; [@ref-45]). Second, we calculated a replication BF for the correlations for each region as a measure of replication success. This test compares the predictive adequacy of the null hypothesis *H*~0~ (i.e., no correlation) with an alternative hypothesis *H*~r~. The alternative hypothesis is defined as the posterior distribution of the correlation coefficient derived from the original study, assuming a uniform prior before seeing the data of the original study ([@ref-46]). We slightly modified of the following source code <http://www.josineverhagen.com/wp-content/uploads/2013/07/RepfunctionscorrelationFINAL1.txt> (for plotting purposes) to the code which can be found online at the following address: <https://osf.io/x9gjj/>. This code was executed using RStudio ([@ref-38]) with R 3.3.2 ([@ref-37]). We also reanalysed the results of [@ref-25] with these methods. Bayes factors assess the relative likelihood of the observed data under competing hypotheses, yielding a ratio of the relative evidence for one hypothesis over the other. For instance, a BF~01~ below 3 indicates weak or anecdotal evidence, a BF~01~\>3 moderate and a BF~01~ \>10 strong evidence in favour of the null against the alternative ([@ref-21]). In this paper, all BFs are presented as the likelihood of the null hypothesis relative to the alternative hypothesis (i.e., BF~0−~ specifying a negative correlation as alternative; BF~0r~ specifying the posterior probability distribution of the original correlation as alternative). The differences between the default and the replication BF tests can be expressed as follows: the default test addresses the question of whether an effect was present or absent given relatively little prior knowledge of the effect size, while the replication test asks whether the effect was similar to what was found before, or absent ([@ref-46]).

Two potential sources of bias for this analysis were the inclusion of twin pairs, and the use of cerebellar grey matter as the reference region ([@ref-17]). We therefore performed two additional analyses by (1) randomly excluding one twin from each twin pair (using <http://www.random.org>), resulting in a sample size of 31, and (2) using the white matter as a reference region for hippocampus and frontal cortex.

Results
=======

In the present sample of 50 subjects, the BP~ND~ of \[^11^C\]WAY100635 varied about 4-fold between individuals ([Table 1](#table-1){ref-type="table"}). ST scores ranged from 2 to 24 (mean 9.7, SD 5.8); the SA scores ranged from 0 to 12 (mean 3.9, SD 3.1) ([Table 1](#table-1){ref-type="table"}). There were no significant correlations between regional 5-HT~1A~ receptor binding and scores on ST or SA ([Fig. 1](#fig-1){ref-type="fig"}, [Table 2](#table-2){ref-type="table"}).
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###### TCI scores and BP~ND~ in the original study ([@ref-3]) and the present replication study.

![](peerj-06-5790-g003)

                        Original study   Replication                
  --------------------- ---------------- ------------- ------------ ------------
  TCI scores                                                        
  ST                    9.4 (3.8)        3--15         9.7 (5.8)    2--24
  SA                    4.7 (3.0)        0--9          3.9 (3.1)    0--12
  BP~ND~ values                                                     
  Dorsal raphe nuclei   2.2 (0.87)       0.81--4.11    1.7 (0.48)   0.64--2.88
  Hippocampus           4.7 (1.49)       1.91--7.15    5.1 (1.41)   2.27--8.14
  Frontal cortex        3.2 (0.90)       1.60--4.55    3.3 (0.73)   1.21--4.61

**Notes.**

AbbreviationsTCITemperament and Character InventorySTself-transcendenceSAspiritual acceptanceBP~ND~binding potential

![Correlation between self-transcendence (ST) and spiritual acceptance (SA) scales on TCI and 5-HT~1A~ receptor binding potential (BP~ND~) in frontal cortex, dorsal raphe nuclei and hippocampus in 50 healthy men\
(A) Self-transcendence in frontal cortex. (B) Self-transcendence in hippocampus. (C) Self-transcendence in dorsal raphe nuclei. (D) Spiritual acceptance in frontal cortex. (E) Spiritual acceptance in hippocampus. (F) Spiritual acceptance in dorsal raphe nuclei. Abbreviations: TCI, Temperament and Character Inventory.](peerj-06-5790-g001){#fig-1}
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###### Pearson's *r*, default BF and replication BF for 5-HT~1*A*~ BN~ND~ and self- transcendence/spiritual acceptance for frontal cortex, hippocampus and dorsal raphe nuclei for present & Karlsson's replication.
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                                                          Pearson's *r*   *P*-value   Present Replication   Karlsson Replication         
  ------------------------------------------------------- --------------- ----------- --------------------- ---------------------- ----- ------
  **Self-transcendence (ST)**                                                                                                            
  \- frontal cortex                                       −0.06           0.70        5.3                   8.1                    4.8   7.6
  \- hippocampus                                          −0.19           0.20        2.5                   2.3                    5.0   9.0
  \- dorsal raphe nuclei                                  −0.11           0.46        4.3                   6.4                    1.8   2.4
  **Spiritual acceptance vs material rationalism (SA)**                                                                                  
  \- frontal cortex                                       −0.03           0.86        5.6                   12.8                   6.0   12.3
  \- hippocampus                                          −0.12           0.41        4.1                   31.5                   4.0   33.8
  \- dorsal raphe nuclei                                  −0.16           0.27        3.1                   21.2                   2.6   17.8

**Notes.**

AbbreviationsTCITemperament and Character Inventory*r*Pearson's correlation efficientBF~0−~the default BF representing the relative likelihood of the null hypothesis (*H*~0~: no correlation) compared to the alternative hypothesis (*H* − : negative correlation), given the dataBF~0*r*~replication BF representing the relative likelihood of the null hypothesis (*H*~0~ : no correlation) compared to the alternative hypothesis *H*~*r*~ obtained from the original study (*H*~*r*~ : posterior of *ρ* given the original study), given the data

All BF favoured the null over the alternative hypotheses. Default correlation BFs ranged from 2.5 to 5.6 in favour of the null ([Table 2](#table-2){ref-type="table"}), meaning that the null hypothesis of no correlation is 2.5 to 5.6 times more likely than the alternative hypothesis for a negative correlation, given the data. For the results of [@ref-25], default correlation BFs ranged from 1.8 to 6.0. Nine out of 12 default BFs provided moderate evidence in favour of the null hypothesis; the remaining three provided only weak evidence ([Table 2](#table-2){ref-type="table"}).

The replication BFs ranged from 2.3 to 31.5 in favour of the null hypothesis ([Table 2](#table-2){ref-type="table"}); replication BFs for [@ref-25] ranged from 2.4 to 33.8. Ten out of 12 replication BFs provided moderate to strong evidence in favour of the null hypothesis. The remaining two replication BFs provided only weak evidence ([Table 2](#table-2){ref-type="table"}).

[Figure 2](#fig-2){ref-type="fig"} illustrates the replication BF, showing how the data from the replication study shifts the distribution from the original study towards a correlation coefficient close to zero.

![Prior and posterior probability distributions for the correlation coefficient for the Bayesian test for replication of the correlation between self-transcendence/spiritual acceptance and 5-HT~1A~ BP~ND~.\
(A) Self-transcendence in frontal cortex. (B) Self-transcendence in hippocampus. (C) Self-transcendence in dorsal raphe nuclei. (D) Spiritual acceptance in frontal cortex. (E) Spiritual acceptance in hippocampus. (F) Spiritual acceptance in dorsal raphe nuclei. The curves represent conditional probability distributions, *π*, of the correlation coefficient (*ρ*), given the data (*d*) for the original (ori), replication (rep) and both studies together (all). *π*(*ρ*) represents the uniform prior distribution assumed for the original study ([@ref-3]). *π*(*ρ*\|*d*~ori~) represents the posterior distribution of the original study. *π*(*ρ*\|*d*~rep~) represents the posterior distribution of the replication study, assuming a uniform prior (i.e., without taking the results of the original study into consideration---the posterior based on a uniform prior on *ρ*). *π*(*ρ*\|*d*~all~) represents the posterior distribution of the replication study using the posterior distribution of the original study as prior (i.e., the posterior distribution taking the results of both studies into consideration). The grey points indicate the height of the prior and posterior distributions at the sceptic's null hypothesis that the effect size is zero. The ratio of these two points is the replication BF. Abbreviations: BF~0*r*~, replication BF representing the relative likelihood of the null hypothesis (*H*~0~ no correlation) compared to the alternative hypothesis *H*~*r*~ obtained from the original study (*H*~*r*~: posterior of *ρ* given the original study), given the data.](peerj-06-5790-g002){#fig-2}

The results did not greatly differ after repeating the analysis to account for biases, either by randomly excluding one twin from each twin pair, or by using white matter as reference region (see [Supplemental Information 1](#supp-1){ref-type="supplementary-material"}).

Discussion
==========

The aim of the present study was to perform a replication of our previous study ([@ref-3]) in a larger sample. We were not able to find any significant relationships between 5-HT~1A~ receptor availability and ST/SA for any of the three regions. This is in line with the results of Karlsson and co-authors in an earlier replication study ([@ref-25]). Instead, in both this study and in our reanalysis of the results of [@ref-25], Bayesian analysis provided more support for the null-hypothesis i.e., that 5-HT~1A~ receptor is not related to the propensity for extraordinary or transcendental experiences

Despite the present results, the serotonin system remains of interest in research on the biological underpinning of personality traits associated with extraordinary experiences. 5-HTT (serotonin transporter) has been linked to ST in both a PET study ([@ref-26]), and in genetic studies---though results are conflicting ([@ref-32]; [@ref-1]; [@ref-39]). Furthermore, 5-HT~1A,~5-HT~2A~ and 5-HT6 receptor gene polymorphisms have been shown to be correlated to ST ([@ref-16]; [@ref-28]).

Pharmacological research shows that the serotonin system plays a key role in the effects of hallucinogens, which produce psychosis-like symptoms (comparable to some of the items in the SA scale) ([@ref-44]; [@ref-14]). Moreover, treatment with SSRI in depressed patients lowered ST scores ([@ref-19]).

Hence, although we failed to replicate the association between 5-HT~1A~ and ST/SA, these lines of evidence motivate further research to clarify the role of serotonin neurotransmission and ST/SA in the healthy population as well as in patients.

The present study was performed on an independent sample of healthy male individuals. Compared to our original study, the sample exhibited less variance in age, and 38 of the 50 subjects were twin pairs. TCI scores and BP~ND~ values were however similar to the original study, therefore the more homogenous age range and genetic background of the present sample are unlikely to fully explain the difference in results. Furthermore, we used more advanced image processing methods than in our original study (although many of these, such as automated region of interest (ROI) definition and frame-by-frame realignment of the PET images, were also used in the study by Karlsson and colleagues ([@ref-18]; [@ref-25]). We were not able to reanalyse the data of the original study using these methods, since T1 weighted MR images were not collected in this sample. However, automated ROIs have been shown to exhibit similar reliability compared to manual ([@ref-23]), suggesting that methodological factors are unlikely to explain the discrepancies.

Replication failure is a common problem in science: in clinical trials and psychology studies replication rates range from 11 to 39%, respectively ([@ref-2]; [@ref-34]). Both previous studies on 5-HT~1A~ and ST/SA had low power due to small sample sizes and multiple comparisons without correction, possibly leading to incorrect inferences. According to our calculations using PPV (positive predictive value; the probability that a 'positive' research finding reflects a true effect) ([@ref-8]) the probability that our original finding was true was only around 9%, even before consideration of the two replication studies (see [Supplemental Information 1](#supp-1){ref-type="supplementary-material"} for the assumptions and the calculation).

Limitations
-----------

Our data consisted of males only. We excluded women from the analysis since the literature is conflicting about the effect of gender and menstrual cycles on 5-HT~1A~ receptor binding ([@ref-35]; [@ref-42]; [@ref-9]; [@ref-36]; [@ref-10]; [@ref-24]; [@ref-41]; [@ref-31]) and gender influences ST scores on TCI ([@ref-6]; [@ref-13]). Additionally, we wanted to replicate our original study, which contained only males, as closely as possible. Therefore, caution must be exercised when generalizing the present finding in male subjects to the female population. Karlsson and co-authors studied a gender mixed sample (11 males/nine females) in their previous negative study ([@ref-25]), and in genetic studies the association between serotonin genes and ST/SA has in some studies been reported to differ between gender ([@ref-32]; [@ref-1]) whereas others found no difference ([@ref-28]; [@ref-39]).

The same is true for age: we had a similar sample to the original study, with limited range, and age might influence both ST scores and 5-HT~1A~ binding ([@ref-27]; [@ref-6]; [@ref-31]).

As in the original study, we used the cerebellar grey matter as a reference region, which is not considered the gold standard due to small levels of specific binding in this region ([@ref-40]). However, using arterial plasma to calculate BP~P~ and BP~ND~ using cerebellar white matter as reference, Karlsson and co-authors could not replicate the original findings either ([@ref-25]). In addition, our analysis using cerebellar white matter showed similar results (see [Supplemental Information 1](#supp-1){ref-type="supplementary-material"}).

Strengths
---------

Where Karlsson and co-authors could only conclude that they did not find a significant correlation between ST/SA and 5-HT~1A~ receptor binding ([@ref-25]), using Bayesian hypothesis testing, we were able to conclude that the data supplied more evidence in favour of the null hypothesis (i.e., no correlation) for both our data and for that of [@ref-25]. Furthermore, the replication BF allowed us to take the magnitude of our previous results and its uncertainty fully into account. In this way, using the current data, the replication BF results suggest that the effect reported by the original study was likely either to be overestimated or a false positive. As such, these results support the conclusion that there is little to no association between ST/SA and 5-HT~1A~ receptor binding.

Of wider interest in the field of molecular imaging is that Bayesian hypothesis testing provides more informative conclusions than traditional *p*-values, thus offering pragmatic advantages for analysis of expensive neuroimaging studies, where limited sample sizes are common. For instance, Bayesian hypothesis testing allows for collecting data until the evidence is sufficiently strong to make a conclusion for one or the other hypothesis without requiring correction for multiple comparisons with sequential analyses. In this way, both costs and radiation exposure can be decreased.

Conclusions
===========

In conclusion, we failed to replicate our previous finding of a negative association between ST/SA and 5-HT~1A~ receptor binding. Rather, our Bayesian analysis found more evidence for a lack of correlation. Further research should focus on whether other components of the serotonin system may be related to ST/SA.
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